Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2024-09-23 Capital/Financing Update
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT - CHANGE IN USE OF PROCEEDS
Capital/Financing Update Classification · 95% confidence The document is an announcement from Ascletis Pharma Inc. regarding a change in the use of proceeds from its Global Offering. It references previous announcements and the 2023 Annual Report but does not contain full financial statements or detailed financial performance data. The document is focused on updating shareholders and the market about how the company plans to reallocate unutilized funds from the offering. It is not a full annual or interim report, nor is it a certification or a voting result. The content fits the category of a Capital/Financing Update as it deals with the use of proceeds from capital raised. The document length (7,718 characters) and detailed explanation support this classification with high confidence.
2024-09-23 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ENTERS THE OBESITY DRUG SPACE WITH ANNOUNCEMENT OF TWO ONGOING U.S. PHASE I CLINICAL TRIALS UTILIZING ITS SMALL MOLECULE GLP-1R AGONIST ASC30 FOR BOTH ONCE-MONTHLY SU
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the initiation and progress of two Phase I clinical trials for a new obesity drug candidate ASC30. It includes detailed information about the drug's properties, trial design, dosing, and expected data release timeline. There is no financial data, no regulatory filing of financial results, no shareholder voting results, no management or board changes, and no mention of annual or interim reports. The document is a business update focused on clinical development progress and drug pipeline news. It is not a report but an announcement of ongoing clinical trials and business development. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory/business update announcement that does not fit other specific categories.
2024-09-17 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosure of such changes. The content includes detailed tables of share repurchases, treasury shares, prices, and dates, as well as confirmations about compliance with repurchase mandates. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about share repurchase activity and changes in capital structure. This fits the definition of a 'Transaction in Own Shares' filing, which covers company buybacks or sales of its own shares. The document length and detail confirm it is the report itself, not just an announcement of a report publication or a certification. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2024-09-17 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosure of such changes. The content includes detailed tables of share repurchases, treasury shares, repurchase prices, and confirmation statements about compliance with exchange rules. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about share repurchase activity and changes in capital structure. This fits the definition of a 'Transaction in Own Shares' filing, which covers company buybacks or sales of its own shares. The document length and detail confirm it is the report itself, not just an announcement of a report. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2024-09-16 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosures of share repurchases and changes in issued shares. The content includes detailed tables of share repurchase transactions, dates, prices, and confirmations that the repurchases were made in accordance with exchange rules. There is no financial performance data, earnings information, or management discussion. The document is a regulatory disclosure about share repurchases and treasury share transactions, which fits the category of Transaction in Own Shares (POS). The document length is over 10,000 characters and contains substantive data, so it is not a mere announcement or certification. Therefore, the appropriate classification is POS with high confidence.
2024-09-11 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) governing disclosure of such changes. The content includes detailed tables of share repurchases, treasury shares, prices, and dates, as well as confirmations of compliance with exchange rules. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a regulatory disclosure about share repurchase activity and changes in capital structure. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares. The document length and detail confirm it is the report itself, not just an announcement of a report publication or a certification. Therefore, the correct classification is POS with high confidence.
2024-09-09 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.